By characterizing the gene–drug sensitivity pair of ARAF p.S214C and sorafenib, this study may help establish ARAF p.S214C mutation as a novel biomarker for predicting sorafenib efficacy, which could implicate a new precision medicine strategy for lung cancer. Here, ARAF is linked to lung carcinoma.